Published in Medical Letter on the CDC and FDA, October 23rd, 2005
CAIV-T is MedImmune's investigational, refrigerator-stable formulation of FluMist (influenza vaccine live, intranasal), a frozen vaccine approved to prevent influenza in healthy children and adolescents, 5 to 17 years of age, and healthy adults, 18 to 49 years of age. Included in the sBLA are data from a recently completed pivotal phase 3 study comparing the immunogenicity of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.